tert-butyl 3-(cyclohexylcarbamoyl)piperidine-1-carboxylate | 872508-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 3-(cyclohexylcarbamoyl)piperidine-1-carboxylate
• CAS: 872508-06-0
• 化学式: C₁₇H₃₀N₂O₃
• 分子量: 310.437
• InChiKey: TVMPYKSFITWGEV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  58.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-(cyclohexylcarbamoyl)piperidine-1-carboxylate 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 生成 N-cyclohexylpiperidine-3-carboxamide hydrochloride
  参考文献：
  名称：

  Quinoxalinylurea derivatives as a novel class of JSP-1 inhibitors

  摘要：

  A series of quinoxalinylurea-based inhibitors are synthesized and shown to be the novel and potent inhibitors against Jnk Stimulatory Phosphatase-1 (JSP-1), which is a special member of dual-specificity protein phosphatase (DSP) family. Biological assay and computational modeling studies showed the compounds were reversible and noncompetitive inhibitors of JSP-1. JSP-1 inhibitors may be useful for the treatment of inflammatory, vascular, neurodegenerative, metabolic, and oncological diseases in humans associated with dysfunctional Jnk signaling. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.094
• 作为产物：
  描述：

  3-哌啶甲酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 tert-butyl 3-(cyclohexylcarbamoyl)piperidine-1-carboxylate
  参考文献：
  名称：

  Quinoxalinylurea derivatives as a novel class of JSP-1 inhibitors

  摘要：

  A series of quinoxalinylurea-based inhibitors are synthesized and shown to be the novel and potent inhibitors against Jnk Stimulatory Phosphatase-1 (JSP-1), which is a special member of dual-specificity protein phosphatase (DSP) family. Biological assay and computational modeling studies showed the compounds were reversible and noncompetitive inhibitors of JSP-1. JSP-1 inhibitors may be useful for the treatment of inflammatory, vascular, neurodegenerative, metabolic, and oncological diseases in humans associated with dysfunctional Jnk signaling. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.094

文献信息

• Nickel-catalyzed transamidation of aliphatic amide derivatives
  作者：Jacob E. Dander、Emma L. Baker、Neil K. Garg

  DOI：10.1039/c7sc01980g

  日期：——

  in the transamidation of primary amides, the transamidation of secondary amides has remained underdeveloped, especially when considering aliphatic substrates. Herein, we report a two-step approach to achieve the transamidation of secondary aliphatic amides, which relies on non-precious metal catalysis. The method involves initial Boc-functionalization of secondary amide substrates to weaken the amide

  转酰胺基化或一种酰胺向另一种酰胺的转化是有机合成中的长期挑战。尽管伯酰胺的氨基转移已经取得了显着进展，但仲酰胺的氨基转移仍未得到很好的发展，特别是在考虑脂肪族底物的情况下。在本文中，我们报告了一种分步进行的方法，以实现仲脂族酰胺的氨基转移，该方法依赖于非贵金属催化。该方法涉及仲酰胺底物的初始Boc官能化，以削弱酰胺C–N键。随后在合适的胺偶联剂存在下用镍催化剂处理，然后得到净的转酰胺基产物。该转化在一系列底物上以合成有用的产率进行。一系列竞争实验描述了选择性模式，该模式应影响未来的合成设计。此外，带有可差向立构立体中心的Boc活化仲酰胺衍生物的转氨基作用强调了该方法的温和性和合成实用性。这项研究为迄今为止报道的仲酰胺转酰胺基团的经典问题提供了最通用的解决方案。
• N-substituted piperidines and their use as pharrmaceuticals
  申请人：Yao Wenqing

  公开号：US20060004049A1

  公开（公告）日：2006-01-05

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

  本发明涉及11-β羟基类固醇脱氢酶类型1的抑制剂、矿物皮质激素受体（MR）的拮抗剂以及其药物组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶类型1的表达或活性有关的各种疾病，以及与醛固酮过量有关的疾病。
• N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS
  申请人：Yao Wenqing

  公开号：US20120040964A1

  公开（公告）日：2012-02-16

  The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.

  本发明涉及11-β羟基类固醇脱氢酶1型的抑制剂，矿物质皮质激素受体（MR）的拮抗剂以及其制药组合物。本发明的化合物可用于治疗与11-β羟基类固醇脱氢酶1型的表达或活性有关的各种疾病和/或与醛固酮过多相关的疾病。
• EP1758580A4
  申请人：——

  公开号：EP1758580A4

  公开（公告）日：2008-01-16
• US8071624B2
  申请人：——

  公开号：US8071624B2

  公开（公告）日：2011-12-06